Halozyme Therapeutics Q2 Adj $0.91 Beats $0.78 Estimate, Sales $231.35M Beat $208.90M Estimate
Portfolio Pulse from Benzinga Newsdesk
Halozyme Therapeutics (NASDAQ:HALO) reported Q2 earnings of $0.91 per share, beating the analyst estimate of $0.78 by 16.67%. Sales were $231.35M, surpassing the $208.90M estimate by 10.75%. Both earnings and sales showed year-over-year growth.
August 06, 2024 | 8:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Halozyme Therapeutics reported strong Q2 earnings and sales, both beating analyst estimates and showing year-over-year growth.
The company's strong financial performance, with earnings and sales both exceeding expectations and showing year-over-year growth, is likely to positively impact the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100